University of Pecs Launches Observational Clinical Study to Identify Biomarkers for Hyperacute Brain Injury
Diagnostic Gaps in Acute Brain Injury: The Need for Hyperacute Phase Research
When traumatic brain injury (TBI) or cardiac arrest occurs, specific proteins are immediately released into the bloodstream due to neuronal cell death. However, globally, data on biomarker patterns during the hyperacute phase—such as immediately after ambulance transport or emergency room admission—are extremely limited. A research team from the University of Pecs in Hungary has planned an observational clinical study to secure this diagnostic golden time and precisely predict outcomes. This study holds significant clinical value in preventing secondary brain injuries caused by delayed initial diagnosis and maximizing treatment efficiency.
Precision Diagnosis through Multifaceted Biomarker Analysis
This study expands the analysis scope beyond traditional protein biomarkers such as S100B, glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL) to include microRNA (miRNA) and lipid metabolites. This approach aims to overcome the limitations of measuring only single protein levels and to understand brain cell injury mechanisms in a multidimensional, multi-omics perspective. By constructing a complex biomarker panel, it is expected that the extent of brain cell injury and recovery potential in individual patients can be diagnosed more precisely.
Real-Time Dynamic Assessment Based on Continuous Blood Sampling
The research team has adopted a design to collect blood samples from patients at defined time intervals, starting from the initial emergency response phase before hospital arrival through the first 24 hours after admission. The study will compare three groups: TBI patients, cardiac arrest survivors, and control patients admitted to the emergency room. By tracking the kinetics of biomarker concentration changes in real time, the study aims to increase diagnostic reliability and clearly define the optimal time window for detecting acute brain injury through blood tests.
Data Collection in Standard Treatment Settings and Integration with Diagnostic Device Development
The study will focus exclusively on patients receiving standard of care without experimental drug interventions. This rigorous approach aims to eliminate confounding variables caused by artificial drug interventions and to observe biomarker level changes purely based on physiological responses. The collected clinical data are expected to serve as a crucial benchmark for accelerating the development of point-of-care testing (POCT) devices and diagnostic kits, as well as for enabling rapid decision-making in emergency medical systems.
As the global traumatic brain injury (TBI) diagnostic and evaluation device market is projected to grow rapidly from $323 million in 2023 to $6.32 billion by 2032, the importance of discovering relevant biomarkers is increasing. Currently, Abbott (ABT) has secured a market lead with its 'i-STAT TBI' test, which received FDA bedside point-of-care approval in March 2024. However, the discovery of advanced biomarkers remains essential for diagnosing subtle changes in the hyperacute phase and long-term outcomes. The University of Pecs' observational study (Observational Study) aims to overcome the limitations of existing diagnostic tools by validating a multi-omics approach that includes protein biomarkers such as S100B, GFAP, and NfL, as well as microRNA and lipid metabolites. In the short term, this will improve the accuracy of triage and outcome diagnosis for emergency patients, and in the medium to long term, it will provide key clinical evidence and commercial opportunities for companies developing next-generation liquid biopsy-based TBI point-of-care testing (POCT) devices and analytical software.
Source: ClinicalTrials.gov (api_ct)